To directly test the capacity for CB2R activation to inhibit viral infection, we pretreated activated CD4+ T cells with a potent and selective CB2R agonist that is approximately 200-fold selective for CB2R over CB1R (Ki = 3.4 nM) [39] (JWH-133) prior to HIV-1 exposure. This evidence concerns the gene CD4 and viral infectious disease.